ATRIANCE: Uses, Dosage & Side Effects
A purine nucleoside analogue for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)
ATRIANCE (nelarabine) is an antineoplastic agent belonging to the class of purine nucleoside analogues. It is used to treat patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has relapsed after or failed to respond to at least two prior chemotherapy regimens. Nelarabine is a prodrug that is converted to its active form ara-G, which preferentially accumulates in T-cells, leading to DNA synthesis inhibition and cancer cell death. ATRIANCE is administered as an intravenous infusion in a hospital setting and requires careful monitoring, particularly for neurological side effects. It has been approved under exceptional circumstances due to the rarity of the diseases it treats.
Quick Facts: ATRIANCE
Key Takeaways
- ATRIANCE (nelarabine) is a targeted chemotherapy drug specifically designed for T-cell malignancies. Its active metabolite ara-G preferentially accumulates in T-lymphoblasts, making it uniquely effective against T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
- The most significant risk associated with ATRIANCE is neurotoxicity, which can manifest as drowsiness, seizures, peripheral neuropathy, and in severe cases, ascending paralysis. These neurological side effects may not be fully reversible and require close monitoring throughout treatment.
- ATRIANCE is administered as an intravenous infusion in a hospital setting. Adults receive 1,500 mg/m² over 2 hours on days 1, 3, and 5 of each cycle, while children receive 650 mg/m² over 1 hour daily for 5 consecutive days, with cycles repeated every 21 days.
- The drug causes significant bone marrow suppression, leading to decreased white blood cells, red blood cells, and platelets. Regular blood monitoring is essential, and patients face increased risk of serious infections and bleeding during treatment.
- ATRIANCE is not recommended during pregnancy or breastfeeding due to potential harm to the baby. Both men and women should use effective contraception during and after treatment, and male patients should discuss fertility preservation before starting therapy.
What Is ATRIANCE and What Is It Used For?
ATRIANCE contains the active substance nelarabine, which belongs to a group of medicines called antineoplastic agents used in chemotherapy to kill certain types of cancer cells. Nelarabine is classified as a purine nucleoside analogue, a subclass of antimetabolites that interfere with DNA synthesis in rapidly dividing cells. What distinguishes nelarabine from many other chemotherapy agents is its remarkable selectivity for T-cells, making it particularly valuable in treating T-cell malignancies where treatment options are often limited.
Nelarabine is a prodrug, meaning it requires metabolic conversion in the body to become active. After intravenous administration, nelarabine is rapidly demethylated by the enzyme adenosine deaminase (ADA) to form 9-β-D-arabinofuranosylguanine (ara-G), the pharmacologically active compound. Ara-G is then transported into cells and phosphorylated by intracellular kinases, ultimately forming ara-G triphosphate (ara-GTP). This active triphosphate form preferentially accumulates in T-lymphoblasts due to their relatively higher activity of the enzyme deoxycytidine kinase compared with other cell types. The accumulation of ara-GTP leads to its incorporation into DNA during replication, causing inhibition of DNA synthesis, cell cycle arrest, and programmed cell death (apoptosis).
The preferential accumulation of ara-GTP in T-cells is the pharmacological basis for ATRIANCE's clinical efficacy in T-cell malignancies. This selectivity was first identified in studies of patients with inherited adenosine deaminase deficiency, a condition that leads to accumulation of deoxyguanosine triphosphate (dGTP) and selective T-cell toxicity. Nelarabine was designed to exploit this metabolic vulnerability of T-lymphocytes therapeutically.
ATRIANCE is specifically indicated for the treatment of patients with the following conditions:
- T-cell acute lymphoblastic leukemia (T-ALL): T-ALL is a type of blood cancer characterized by the abnormal proliferation of immature T-lymphocytes (T-lymphoblasts) in the bone marrow and blood. These malignant cells crowd out normal blood cell production, leading to anemia, increased susceptibility to infections, and bleeding problems. T-ALL accounts for approximately 10–15% of pediatric ALL cases and 20–25% of adult ALL cases. While many patients respond to initial chemotherapy, those with relapsed or refractory disease have a very poor prognosis and limited treatment options.
- T-cell lymphoblastic lymphoma (T-LBL): T-LBL is a closely related malignancy in which T-lymphoblasts predominantly form masses in lymph nodes, the thymus (mediastinum), or other organs rather than primarily affecting the bone marrow and blood. T-LBL represents approximately 2% of all non-Hodgkin lymphomas in adults and about 30% of lymphoblastic lymphomas. It is considered the same biological entity as T-ALL along a clinical spectrum, distinguished primarily by the degree of bone marrow involvement.
ATRIANCE is used in patients whose T-ALL or T-LBL has not responded to (refractory disease) or has returned after (relapsed disease) at least two prior chemotherapy regimens. These patients represent a population with very limited remaining treatment options and a significant unmet medical need. The drug was developed to address this critical gap in the treatment armamentarium for T-cell malignancies.
ATRIANCE has been approved under exceptional circumstances by the European Medicines Agency (EMA). This designation reflects the rarity of T-ALL and T-LBL, which made it impossible to conduct large-scale randomized controlled trials. The approval was based on response data from two open-label clinical studies. The EMA reviews all new information annually and may update the prescribing information as needed. Despite the limited data, ATRIANCE fills a critical treatment gap for patients with few remaining options.
What Should You Know Before Receiving ATRIANCE?
Contraindications
ATRIANCE must not be administered if you have a known hypersensitivity (allergic reaction) to nelarabine or to any of the excipients in the formulation. These excipients include sodium chloride, hydrochloric acid, sodium hydroxide, and water for injections. Before starting treatment, your healthcare provider will confirm that you have no known allergies to these components.
While hypersensitivity is the only absolute contraindication listed in the product information, there are numerous important warnings and precautions that may effectively preclude the use of ATRIANCE in certain patients. Your doctor will carefully weigh the benefits against the risks based on your individual clinical situation.
Warnings and Precautions
Severe neurological side effects have been reported with ATRIANCE treatment. These can include altered mental status (such as extreme drowsiness and confusion), seizures, peripheral neuropathy (numbness, tingling, weakness), and ascending peripheral neuropathies resembling Guillain-Barré syndrome, which can progress to paralysis. These neurological events may not be fully reversible even after treatment is stopped. Your doctor will perform regular neurological assessments throughout your treatment. If you experience any neurological symptoms, report them immediately.
Before and during treatment with ATRIANCE, your doctor must be informed about the following conditions:
- Kidney or liver problems: If you have impaired kidney or liver function, your dose of ATRIANCE may need to be adjusted. The drug and its metabolites are partially eliminated through the kidneys, and compromised renal function may lead to increased drug exposure and greater risk of side effects, particularly neurotoxicity.
- Vaccinations: If you have recently been vaccinated or are planning to receive a vaccination with a live vaccine (such as polio, varicella, typhoid, or BCG), you must inform your doctor. Patients receiving ATRIANCE are immunosuppressed and may be at risk of vaccine-strain infection from live vaccines. Inactivated vaccines may also be less effective during treatment due to impaired immune response.
- Blood disorders: If you have any pre-existing blood problems such as anemia, low white blood cell counts, or low platelet counts, your doctor needs to know. ATRIANCE causes significant bone marrow suppression, and starting with already compromised blood counts may increase the risk of serious complications such as life-threatening infections or severe bleeding.
- Previous neurological conditions: If you have any history of neurological disease or have previously experienced neurotoxicity from other medications, this may increase your vulnerability to the neurological side effects of ATRIANCE. Your doctor will carefully evaluate your neurological baseline before starting treatment.
Your doctor will perform regular blood tests throughout your treatment to monitor your blood cell counts and detect any blood-related complications early. Complete blood counts should be obtained at regular intervals during treatment. If severe hematological toxicity develops, your doctor may delay or modify subsequent treatment cycles.
If you are an older adult, you may be more susceptible to the neurological side effects of ATRIANCE. Your doctor will monitor you more closely during treatment and may adjust the treatment plan accordingly. Clinical experience in elderly patients is limited.
Pregnancy and Breastfeeding
ATRIANCE is not recommended for use in pregnant women. Based on its mechanism of action as a DNA synthesis inhibitor, nelarabine has the potential to cause significant harm to a developing fetus if conceived before, during, or shortly after treatment. Women of childbearing potential should use effective contraception during treatment and discuss appropriate contraceptive methods with their doctor. If pregnancy does occur during treatment, the doctor must be informed immediately so that the potential risks to the fetus can be assessed.
Male patients who wish to father a child should seek their doctor's advice regarding family planning or treatment options before starting ATRIANCE. Sperm preservation (cryopreservation) should be discussed as an option, as the drug may affect male fertility. Men should not attempt to father a child during treatment and for a period after the last dose, as advised by their doctor.
It is not known whether nelarabine or its metabolites pass into human breast milk. Given the mechanism of action and potential for serious adverse effects in nursing infants, breastfeeding must be discontinued while receiving ATRIANCE. Women should consult their doctor or pharmacist before taking any medication during the treatment period.
Driving and Operating Machinery
ATRIANCE can cause drowsiness, somnolence, dizziness, and other neurological effects that may persist for several days after each treatment cycle. If you experience tiredness, weakness, or any neurological symptoms, do not drive or operate machinery. These effects can significantly impair your ability to perform tasks that require alertness and coordination. Discuss with your doctor when it is safe to resume driving or using machinery.
Important Information About Ingredients
Each 50 ml vial of ATRIANCE contains 88.51 mg (3.85 mmol) of sodium, the main component of table salt. This is equivalent to approximately 4.4% of the WHO-recommended maximum daily dietary intake of sodium for adults (2 g per day). This should be taken into consideration by patients on a controlled sodium diet, particularly when multiple vials are administered per treatment session. Discuss with your doctor if you are on a sodium-restricted diet.
How Does ATRIANCE Interact with Other Drugs?
The potential for drug interactions with ATRIANCE has not been exhaustively studied in formal clinical pharmacokinetic interaction trials. However, based on its metabolic pathway and mechanism of action, several important interactions are known or theoretically significant. Nelarabine is converted to its active metabolite ara-G by adenosine deaminase (ADA), and therefore any drug that affects ADA activity may significantly alter the pharmacokinetics and toxicity of ATRIANCE.
It is essential to inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take, including prescription medications, over-the-counter products, herbal remedies, and dietary supplements. Remember to inform your healthcare team if you start any new medications while receiving ATRIANCE.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Pentostatin (deoxycoformycin) | Inhibits adenosine deaminase, preventing conversion and clearance of ara-G; may dramatically increase ara-G levels and toxicity | Avoid combination – risk of severe and potentially fatal toxicity |
| Fludarabine and other adenosine deaminase-affecting agents | May alter nelarabine/ara-G metabolism; potential for increased myelosuppression and neurotoxicity | Use with extreme caution; close monitoring required |
| Live vaccines (e.g., MMR, varicella, BCG, oral polio, typhoid) | Risk of vaccine-strain infection due to immunosuppression caused by ATRIANCE | Avoid during treatment and for several months after completion |
| Other myelosuppressive agents | Additive bone marrow suppression, increased risk of severe cytopenias | Monitor blood counts closely; dose adjustments may be necessary |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Nephrotoxic agents (e.g., aminoglycosides, NSAIDs, contrast dyes) | May impair renal clearance of ara-G, leading to increased drug exposure | Monitor renal function closely; adjust doses if needed |
| Other neurotoxic agents (e.g., vincristine, cisplatin) | Additive neurotoxicity; may increase risk or severity of peripheral neuropathy | Assess neurological status carefully; consider sequential rather than concurrent use |
| Inactivated vaccines | Reduced immune response; vaccination may be ineffective | Defer vaccination until immune recovery; revaccinate after treatment if needed |
| Allopurinol / rasburicase | No negative interaction; used to prevent tumor lysis syndrome | Commonly co-administered as supportive care; appropriate prophylactic use recommended |
Because formal drug interaction studies for ATRIANCE are limited, patients should maintain a comprehensive list of all their medications and share it with every healthcare provider involved in their care. New medications should not be started during ATRIANCE treatment without first consulting the treating physician.
What Is the Correct Dosage of ATRIANCE?
The dose of ATRIANCE is carefully calculated by your doctor based on your body surface area (BSA), which is determined from your height and weight. Blood test results are also taken into account before each treatment cycle to ensure it is safe to proceed. ATRIANCE is always administered by a doctor or nurse in a hospital or clinic setting as an intravenous infusion (drip), typically into a vein in your arm.
Adults and Adolescents (16 Years and Older)
Adult Dosing Schedule
Dose: 1,500 mg/m² body surface area per day
Administration: Intravenous infusion over approximately 2 hours
Schedule: Given once daily on Day 1, Day 3, and Day 5 of each treatment cycle
Cycle length: 21 days (3 weeks)
Duration: Treatment continues as determined by your doctor, based on how your disease responds and how well you tolerate the medication. Blood tests are performed before each cycle to confirm it is safe to proceed.
Children and Adolescents (21 Years and Younger)
Pediatric Dosing Schedule
Dose: 650 mg/m² body surface area per day
Administration: Intravenous infusion over approximately 1 hour
Schedule: Given once daily for 5 consecutive days (Day 1 through Day 5) of each treatment cycle
Cycle length: 21 days (3 weeks)
Duration: Treatment continues as determined by the treating physician, based on disease response and tolerability. Complete blood counts are monitored regularly.
There is an overlap in age ranges between the adult and pediatric dosing schedules (patients aged 16–21 years). For these patients, the treating physician will determine the most appropriate dosing regimen based on the individual clinical situation, body size, and treatment history.
Dose Adjustments and Modifications
Your doctor may adjust the dose, delay treatment, or discontinue ATRIANCE based on several factors:
- Neurological toxicity: If you develop signs of neurotoxicity (numbness, tingling, seizures, confusion, weakness), treatment may be delayed or permanently discontinued. Neurological side effects are the most common reason for dose modifications with ATRIANCE.
- Hematological toxicity: If blood test results show significantly low white blood cell counts, red blood cell counts, or platelet counts, the next treatment cycle may be delayed until counts have recovered sufficiently.
- Kidney impairment: Patients with reduced kidney function may require dose adjustments, as ara-G is partially eliminated through the kidneys. Your doctor will monitor your kidney function before and during treatment.
- Liver impairment: While specific dose adjustments for hepatic impairment are not well defined in the prescribing information, your doctor will exercise clinical judgment when treating patients with liver problems.
Dosage Summary Table
| Patient Group | Dose | Infusion Time | Schedule |
|---|---|---|---|
| Adults & adolescents ≥16 years | 1,500 mg/m²/day | ~2 hours | Days 1, 3, 5 every 21 days |
| Children & adolescents ≤21 years | 650 mg/m²/day | ~1 hour | Days 1–5 every 21 days |
Stopping Treatment
Your doctor will determine when treatment with ATRIANCE should be discontinued. Treatment is typically stopped if the disease progresses despite therapy, if unacceptable toxicity develops (particularly neurotoxicity that does not resolve), or if the maximum planned number of cycles has been completed. Do not stop treatment on your own without consulting your doctor, even if you are experiencing side effects, as abrupt discontinuation should be managed under medical supervision.
What Are the Side Effects of ATRIANCE?
Like all medicines, ATRIANCE can cause side effects, although not everyone gets them. Most side effects reported with ATRIANCE were observed in both adults and children/adolescents. Some side effects were reported more frequently in adult patients, though the reason for this is not fully understood. The frequency and severity of side effects can vary between individuals and across treatment cycles.
It is important to report any side effects to your healthcare team promptly, particularly neurological symptoms, signs of infection, or unusual bleeding or bruising. Early detection and management of side effects can help prevent serious complications.
Very Common Side Effects
May affect more than 1 in 10 patients
- Infections: increased susceptibility to infections (including pneumonia) due to reduced white blood cell counts; infections can be life-threatening
- Peripheral neuropathy: altered sensation in hands or feet, muscle weakness, difficulty walking, reduced sensitivity to touch or pain, tingling, burning, or crawling sensations on the skin
- Anemia: general feeling of weakness and fatigue; blood transfusions may be required in some cases
- Thrombocytopenia: unusual bruising or bleeding caused by decreased platelets; can lead to severe hemorrhage from minor injuries
- Neutropenia: decreased white blood cells, increasing infection risk significantly
- Drowsiness and somnolence: feeling sleepy, drowsy, or excessively tired
- Headache and dizziness
- Respiratory symptoms: shortness of breath, difficult or labored breathing, cough
- Gastrointestinal effects: nausea, vomiting, diarrhea, constipation
- Muscle pain (myalgia)
- Edema: swelling in various parts of the body due to fluid accumulation
- Fever (pyrexia), fatigue, weakness, malaise
Common Side Effects
May affect up to 1 in 10 patients
- Seizures (convulsions): severe, uncontrollable muscle contractions, often with loss of consciousness
- Ataxia: clumsiness and lack of coordination affecting balance, walking, limb and eye movements, or speech
- Tremor: involuntary rhythmic shaking in one or more limbs
- Musculoskeletal pain: joint pain, back pain, pain in hands and feet, including paresthesias and numbness
- Low blood pressure (hypotension)
- Weight loss and decreased appetite (anorexia)
- Abdominal pain, mouth sores, mouth ulcers, stomatitis
- Cognitive effects: memory problems, disorientation, blurred vision, taste disturbances (dysgeusia) or loss of taste
- Pleural effusion: fluid accumulation around the lungs causing chest pain and breathing difficulty; wheezing
- Elevated bilirubin: may cause yellowing of the skin (jaundice) and extreme fatigue
- Elevated liver enzymes
- Elevated creatinine: a sign of kidney problems, potentially causing decreased urination
- Tumor lysis syndrome: release of tumor cell contents that may cause nausea, vomiting, shortness of breath, irregular heartbeat, cloudy urine, extreme fatigue, and joint problems; most likely at the start of treatment
- Electrolyte imbalances: low calcium (muscle cramps), low magnesium (weakness, confusion, irregular heartbeat), low potassium (weakness), low glucose (nausea, sweating, confusion)
Rare Side Effects
May affect up to 1 in 1,000 patients
- Rhabdomyolysis: a serious condition involving destruction of skeletal muscle, characterized by the presence of myoglobin (a muscle breakdown product) in the urine and elevated creatine phosphokinase levels in the blood; requires immediate medical attention
Contact your healthcare team immediately if you experience any of the following: fever or signs of infection (sore throat, mouth sores, burning sensation during urination), seizures, sudden weakness or numbness in arms or legs, difficulty walking or loss of balance, severe confusion or altered consciousness, unusual bleeding or bruising, or severe difficulty breathing. These may indicate life-threatening complications that require urgent medical intervention.
How Should You Store ATRIANCE?
Proper storage of ATRIANCE is essential to maintain the efficacy and safety of the medication. In most clinical settings, ATRIANCE is stored and prepared by hospital pharmacy staff according to established protocols. However, it is important for patients and caregivers to understand the storage requirements.
ATRIANCE solution for infusion should be stored according to the following guidelines:
- Unopened vials: No special storage conditions are required. The vials can be stored at room temperature.
- After opening: Once the vial has been opened, the solution remains chemically and physically stable for up to 8 hours at temperatures not exceeding 30°C (86°F).
- Expiration date: Do not use this medicine after the expiration date printed on the carton and vial label. The expiration date refers to the last day of that month.
- Keep out of reach of children: Store the medicine where children cannot see or reach it.
- Disposal: Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of unused medicines. These measures help protect the environment. As a cytotoxic agent, ATRIANCE waste should be handled according to institutional protocols for hazardous pharmaceutical waste.
ATRIANCE is a clear, colorless solution supplied in clear glass vials with a rubber stopper and aluminum seal. Each vial contains 50 ml of solution at a concentration of 5 mg/ml, providing 250 mg of nelarabine per vial. The medicine is available in packs of 1 vial or 6 vials. Healthcare professionals handling ATRIANCE should follow standard cytotoxic handling procedures, including the use of protective clothing, gloves, masks, and eye protection. Pregnant staff should not handle this medication.
What Does ATRIANCE Contain?
Understanding the complete composition of ATRIANCE is important for identifying potential allergens and ensuring safe administration. The following is a detailed breakdown of the product's contents:
Active Ingredient
| Component | Amount per ml | Amount per Vial (50 ml) |
|---|---|---|
| Nelarabine | 5 mg | 250 mg |
Inactive Ingredients (Excipients)
- Sodium chloride: Used as a tonicity agent to make the solution compatible with intravenous administration. Contributes 88.51 mg of sodium per vial (see sodium warning in Section 2).
- Water for injections: The vehicle (solvent) for the solution.
- Hydrochloric acid / Sodium hydroxide: Used for pH adjustment to ensure the solution is at the correct pH for safe intravenous infusion.
ATRIANCE solution for infusion is a clear, colorless liquid. It is supplied ready-to-use and does not require reconstitution or dilution before administration. The solution should be visually inspected before use; do not use if the solution is discolored or contains particulate matter. The undiluted solution should be transferred to an infusion bag (polyvinyl chloride or ethylene vinyl acetate) or a glass container prior to administration.
Frequently Asked Questions About ATRIANCE
ATRIANCE (nelarabine) is an anticancer medication specifically designed to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It is used in patients whose disease has not responded to or has returned after at least two prior chemotherapy regimens. The drug works by selectively targeting T-cells through its active metabolite ara-G, which accumulates preferentially in T-lymphoblasts and disrupts DNA synthesis, leading to cancer cell death.
ATRIANCE is given as an intravenous (IV) infusion (drip) in a hospital or clinic by a healthcare professional. For adults and adolescents aged 16 years and older, the infusion is given over approximately 2 hours on days 1, 3, and 5 of each 21-day cycle. For children and adolescents aged 21 years and younger, the infusion is given over approximately 1 hour daily for 5 consecutive days in each 21-day cycle. The solution comes ready to use and does not need to be mixed or diluted.
The most serious side effects of ATRIANCE involve the nervous system. Neurotoxicity can manifest as extreme drowsiness, confusion, seizures, peripheral neuropathy (numbness, tingling, and weakness in hands and feet), and in rare but severe cases, ascending paralysis resembling Guillain-Barré syndrome. These neurological effects may not be fully reversible. Additionally, ATRIANCE causes significant bone marrow suppression, leading to dangerously low blood cell counts that increase the risk of life-threatening infections and severe bleeding.
Yes, ATRIANCE can be used in children and adolescents. The pediatric dosing schedule uses a lower dose of 650 mg/m² per day administered over 1 hour for 5 consecutive days in each 21-day cycle, compared to the adult dose of 1,500 mg/m² over 2 hours on days 1, 3, and 5. The treating physician will determine the most appropriate dosing based on the patient's age, body surface area, and clinical condition. Regular blood monitoring and neurological assessments are essential for all age groups.
ATRIANCE was approved under exceptional circumstances because the diseases it treats — relapsed or refractory T-cell ALL and T-cell lymphoblastic lymphoma — are very rare. This rarity made it impossible to gather the comprehensive clinical data that would normally be required for a standard approval. However, the available evidence demonstrated meaningful clinical benefit in patients with extremely limited treatment options. The European Medicines Agency reviews all new information about ATRIANCE annually and updates the product information as needed.
ATRIANCE is not recommended during pregnancy because its mechanism of action as a DNA synthesis inhibitor means it could potentially harm a developing fetus. Women of childbearing potential should use effective contraception during treatment. If pregnancy occurs while on treatment, the doctor must be informed immediately. Breastfeeding must also be discontinued during ATRIANCE treatment, as it is not known whether nelarabine passes into breast milk. Male patients planning to have children should discuss fertility preservation options with their doctor before starting treatment.
References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official regulatory documentation. The following sources were used:
- European Medicines Agency (EMA). ATRIANCE (nelarabine) – Summary of Product Characteristics. Last updated 2024. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Arranon (nelarabine) injection – Prescribing Information. Revised 2024. Available at: fda.gov
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2025. Available at: nccn.org
- European Society for Medical Oncology (ESMO). Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2024.
- DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136-5142.
- Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. Journal of Clinical Oncology. 2005;23(15):3376-3382.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd edition, 2023. Geneva: WHO.
- British National Formulary (BNF). Nelarabine – Drug Monograph. NICE, 2025. Available at: bnf.nice.org.uk
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed physicians specializing in oncology, hematology, and clinical pharmacology. Our editorial process follows the GRADE framework for evidence assessment and adheres to guidelines from the WHO, EMA, FDA, and NCCN.
All content undergoes multi-stage review: initial drafting by medical writers, clinical accuracy verification by specialist physicians, and final editorial review for clarity and accessibility. Each article is updated regularly to reflect the latest evidence and guideline changes.
iMedic operates with complete editorial independence. We receive no funding from pharmaceutical companies and have no conflicts of interest. Our mission is to provide accurate, unbiased, and accessible medical information to patients, caregivers, and the general public worldwide.
For more information about our editorial standards and team credentials, visit our Medical Team and Editorial Standards pages. If you have questions or notice any errors in this content, please contact us.